OpenJDK project teams will focus work on features such as value types, code reflection, AOT compilation, and structured ...

Presenter: Michael Gazda, Ph.D. The abstracts are scheduled to be posted to the ASCO GI Online Program at 5 PM ET on Monday, January 6. About BXQ-350 Bexion's lead drug candidate is BXQ-350, a ...

NEW HOPE, Pa., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact ...

Joint presentation by Orchestra BioMed and Medtronic leadership to discuss ongoing strategic collaboration for development and commercialization of AVIM Therapy for treatment of uncontrolled ...

RALEIGH, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Parexel, a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences ...

Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced ...

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and ...

Community driven content discussing all aspects of software development from DevOps to design patterns. When the seminal Java whitepaper introduced the language in 1995, it listed seven key benefits ...

Luzerne County is holding a public presentation on the county’s proposed artificial intelligence pilot program at 5 p.m. July 30 at the operations building in Wyoming. The purpose of the event is to ...

On May 16, 2025, FibroBiologics, Inc. (NASDAQ:FBLG) announced a poster presentation at the Society for Investigative Dermatology (SID) Annual Meeting. The poster entitled “Immunomodulatory Potential ...

Our faculty, staff, and students actively disseminate their work through diverse channels, reaching a wide array of audiences. They publish in prestigious academic journals, industry publications, and ...

Affimed N.V., a clinical-stage immuno-oncology company, announced that an abstract on its phase 2 LuminICE-203 study involving the innate cell engager acimtamig in combination with AlloNK has been ...